Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001398344-20-003916
Filing Date
2020-02-21
Accepted
2020-02-21 16:05:20
Documents
1

Document Format Files

Seq Description Document Type Size
1 fp0051105_sc13g.htm SC 13G 111773
  Complete submission text file 0001398344-20-003916.txt   113302
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Subject) CIK: 0001346302 (see all company filings)

EIN.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-90534 | Film No.: 20640032
SIC: 2834 Pharmaceutical Preparations

Mailing Address 888 SEVENTH AVENUE 30TH FLOOR NEW YORK NY 10019
Business Address 888 SEVENTH AVENUE 30TH FLOOR NEW YORK NY 10019 212-257-4410
Sessa Capital (Master), L.P. (Filed by) CIK: 0001618360 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G